| THIRD-PARTY-LOGISTICS-PROVIDER |
THIRD-PARTY-LOGISTICS-PROVIDER |
92%
|
ARCALYST is sold through a third-party logistics provider that distributes primarily through a select network of specialty pharmacies (collectively, "customers"), which deliver the medication to pati… |
| HUADONG |
HUADONG |
90%
|
In February 2022 we entered into two collaboration and license agreements (each, a "Huadong Collaboration Agreement" and together, the "Huadong Collaboration Agreements") with Huadong, pursuant to wh… |
| AZN |
AstraZeneca PLC |
72%
|
velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving pos… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN grap… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA graph: en they are labeled as free goods. The Company is conducting a technology transfer of ARCALYST drug substance manuf… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
en they are labeled as free goods. The Company is conducting a technology transfer of ARCALYST drug substance manufacturing from Regeneron Pharmaceuticals, Inc. (“Regeneron”) to Samsung Biologics C… |
| BIOGEN-MA-INC |
BIOGEN-MA-INC |
62%
|
,083 ) $ ( 7,656 ) $ 261 Huadong ARCALYST 12,000 — — — 12,000 Total Contract Liabilities $ 12,000 $ 45,000 $ ( 37,083 ) $ ( 7,656 ) $ 12,261 13… |
| F-HOFFMANN-LA-ROCHE-LTD |
F-HOFFMANN-LA-ROCHE-LTD |
62%
|
. ASU 2025-06 modernizes and simplifies the accounting for software development costs by establishing a single capitalization framework for all internally developed or acquired software, regardless o… |
| HANGZHOU-ZHONGMEI-HUADONG-PHARMACEUTICAL-CO-LTD |
HANGZHOU-ZHONGMEI-HUADONG-PHARMACEUTICAL-CO-LTD |
62%
|
KINIKSA PHARMACEUTICALS, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Amounts in thousands, except share and per share amounts) obligation in the Genentech License Agreement was det… |
| KINIKSA-PHARMACEUTICALS-GMBH |
KINIKSA-PHARMACEUTICALS-GMBH |
62%
|
uch, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process deve… |
| KINIKSA-PHARMACEUTICALS-INC |
KINIKSA-PHARMACEUTICALS-INC |
62%
|
uch, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process deve… |
| MEDIMMUNE-LIMITED |
MEDIMMUNE-LIMITED |
62%
|
velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving pos… |
| PRIMATOPE-THERAPEUTICS-INC |
PRIMATOPE-THERAPEUTICS-INC |
62%
|
y classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process development and manufactur… |
| SAMSUNG-BIOLOGICS-CO-LTD |
SAMSUNG-BIOLOGICS-CO-LTD |
62%
|
en they are labeled as free goods. The Company is conducting a technology transfer of ARCALYST drug substance manufacturing from Regeneron Pharmaceuticals, Inc. (“Regeneron”) to Samsung Biologics C… |
| UK-LTD |
UK-LTD |
62%
|
uch, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process deve… |
